Our team

Vaderis was founded on the belief that science guided with courage, and carried out with genuine empathy, can change life for people living with rare vascular diseases. In 2019, we turned that belief into action by focusing on one of the field’s most overlooked and life-altering conditions: hereditary hemorrhagic telangiectasia (HHT), a disease with no approved therapies, little global awareness, and a profound impact on patients and families.

That commitment has led to the development of a first-of-its-kind oral therapy designed to restore vascular balance, supported by a targeted AKT inhibition approach.

Our work is grounded in persistence, humility, and collaboration. We are a team of scientists, clinicians, operators and leaders who have spent our careers bringing new medicines to people with complex, underserved diseases. Today, we are channeling that experience into creating real therapeutic options for patients who have long had none.